
A phase I clinical study of zzso administered by 72-hour continuous intravenous infusion was conducted in 13 patients with various types of advanced solid tumors to evaluate the drug's toxicity and zzso The initial dosage of 300 zzso X 3 days repeated at zzso intervals was progressively increased by 150 zzso to a maximum dosage of 750 zzso The zzso zzso were zzso and zzso zzso was more severe than was zzso The lowest zzso count less than zzso occurred during more than half of the treatment courses at doses of 600 zzso and zzso Severe zzso and vomiting were observed in patients during three of four treatment courses at the 750 zzso dose zzso None of the patients had microscopic zzso or symptoms suggestive of zzso zzso response occurred in a patient with zzso cancer zzso to the zzso Disease stabilization occurred in four patients, while six patients had progression of zzso The recommended starting dosage of zzso by continuous intravenous infusion for phase II trials is 600 zzso X 3 every 3 weeks for patients with good bone zzso zzso 

